Cargando…

Serial changes in tumour measurements and apparent diffusion coefficients in prostate cancer patients on active surveillance with and without histopathological progression

OBJECTIVE: To analyse serial changes in MRI-derived tumour measurements and apparent diffusion coefficient (ADC) values in prostate cancer (PCa) patients on active surveillance (AS) with and without histopathological disease progression. METHODS: This study included AS patients with biopsy-proven PC...

Descripción completa

Detalles Bibliográficos
Autores principales: Sushentsev, Nikita, Caglic, Iztok, Rundo, Leonardo, Kozlov, Vasily, Sala, Evis, Gnanapragasam, Vincent J, Barrett, Tristan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The British Institute of Radiology. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8978242/
https://www.ncbi.nlm.nih.gov/pubmed/34538077
http://dx.doi.org/10.1259/bjr.20210842
_version_ 1784680930607104000
author Sushentsev, Nikita
Caglic, Iztok
Rundo, Leonardo
Kozlov, Vasily
Sala, Evis
Gnanapragasam, Vincent J
Barrett, Tristan
author_facet Sushentsev, Nikita
Caglic, Iztok
Rundo, Leonardo
Kozlov, Vasily
Sala, Evis
Gnanapragasam, Vincent J
Barrett, Tristan
author_sort Sushentsev, Nikita
collection PubMed
description OBJECTIVE: To analyse serial changes in MRI-derived tumour measurements and apparent diffusion coefficient (ADC) values in prostate cancer (PCa) patients on active surveillance (AS) with and without histopathological disease progression. METHODS: This study included AS patients with biopsy-proven PCa with a minimum of two consecutive MR examinations and at least one repeat targeted biopsy. Tumour volumes, largest axial two-dimensional (2D) surface areas, and maximum diameters were measured on T (2) weighted images (T (2)WI). ADC values were derived from the whole lesions, 2D areas, and small-volume regions of interest (ROIs) where tumours were most conspicuous. Areas under the ROC curve (AUCs) were calculated for combinations of T (2)WI and ADC parameters with optimal specificity and sensitivity. RESULTS: 60 patients (30 progressors and 30 non-progressors) were included. In progressors, T (2)WI-derived tumour volume, 2D surface area, and maximum tumour diameter had a median increase of +99.5%,+55.3%, and +21.7% compared to +29.2%,+8.1%, and +6.9% in non-progressors (p < 0.005 for all). Follow-up whole-volume and small-volume ROIs ADC values were significantly reduced in progressors (−11.7% and −9.5%) compared to non-progressors (−6.1% and −1.6%) (p < 0.05 for both). The combined AUC of a relative increase in maximum tumour diameter by 20% and reduction in small-volume ADC by 10% was 0.67. CONCLUSION: AS patients show significant differences in tumour measurements and ADC values between those with and without histopathological disease progression. ADVANCES IN KNOWLEDGE: This paper proposes specific clinical cut-offs for T (2)WI-derived maximum tumour diameter (+20%) and small-volume ADC (−10%) to predict histopathological PCa progression on AS and supplement subjective serial MRI assessment.
format Online
Article
Text
id pubmed-8978242
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher The British Institute of Radiology.
record_format MEDLINE/PubMed
spelling pubmed-89782422022-04-11 Serial changes in tumour measurements and apparent diffusion coefficients in prostate cancer patients on active surveillance with and without histopathological progression Sushentsev, Nikita Caglic, Iztok Rundo, Leonardo Kozlov, Vasily Sala, Evis Gnanapragasam, Vincent J Barrett, Tristan Br J Radiol Innovations in prostate cancer special feature : Full Paper OBJECTIVE: To analyse serial changes in MRI-derived tumour measurements and apparent diffusion coefficient (ADC) values in prostate cancer (PCa) patients on active surveillance (AS) with and without histopathological disease progression. METHODS: This study included AS patients with biopsy-proven PCa with a minimum of two consecutive MR examinations and at least one repeat targeted biopsy. Tumour volumes, largest axial two-dimensional (2D) surface areas, and maximum diameters were measured on T (2) weighted images (T (2)WI). ADC values were derived from the whole lesions, 2D areas, and small-volume regions of interest (ROIs) where tumours were most conspicuous. Areas under the ROC curve (AUCs) were calculated for combinations of T (2)WI and ADC parameters with optimal specificity and sensitivity. RESULTS: 60 patients (30 progressors and 30 non-progressors) were included. In progressors, T (2)WI-derived tumour volume, 2D surface area, and maximum tumour diameter had a median increase of +99.5%,+55.3%, and +21.7% compared to +29.2%,+8.1%, and +6.9% in non-progressors (p < 0.005 for all). Follow-up whole-volume and small-volume ROIs ADC values were significantly reduced in progressors (−11.7% and −9.5%) compared to non-progressors (−6.1% and −1.6%) (p < 0.05 for both). The combined AUC of a relative increase in maximum tumour diameter by 20% and reduction in small-volume ADC by 10% was 0.67. CONCLUSION: AS patients show significant differences in tumour measurements and ADC values between those with and without histopathological disease progression. ADVANCES IN KNOWLEDGE: This paper proposes specific clinical cut-offs for T (2)WI-derived maximum tumour diameter (+20%) and small-volume ADC (−10%) to predict histopathological PCa progression on AS and supplement subjective serial MRI assessment. The British Institute of Radiology. 2022-03-01 2021-09-19 /pmc/articles/PMC8978242/ /pubmed/34538077 http://dx.doi.org/10.1259/bjr.20210842 Text en © 2022 The Authors. Published by the British Institute of Radiology https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution 4.0 Unported License http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution and reproduction in any medium, provided the original author and source are credited.
spellingShingle Innovations in prostate cancer special feature : Full Paper
Sushentsev, Nikita
Caglic, Iztok
Rundo, Leonardo
Kozlov, Vasily
Sala, Evis
Gnanapragasam, Vincent J
Barrett, Tristan
Serial changes in tumour measurements and apparent diffusion coefficients in prostate cancer patients on active surveillance with and without histopathological progression
title Serial changes in tumour measurements and apparent diffusion coefficients in prostate cancer patients on active surveillance with and without histopathological progression
title_full Serial changes in tumour measurements and apparent diffusion coefficients in prostate cancer patients on active surveillance with and without histopathological progression
title_fullStr Serial changes in tumour measurements and apparent diffusion coefficients in prostate cancer patients on active surveillance with and without histopathological progression
title_full_unstemmed Serial changes in tumour measurements and apparent diffusion coefficients in prostate cancer patients on active surveillance with and without histopathological progression
title_short Serial changes in tumour measurements and apparent diffusion coefficients in prostate cancer patients on active surveillance with and without histopathological progression
title_sort serial changes in tumour measurements and apparent diffusion coefficients in prostate cancer patients on active surveillance with and without histopathological progression
topic Innovations in prostate cancer special feature : Full Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8978242/
https://www.ncbi.nlm.nih.gov/pubmed/34538077
http://dx.doi.org/10.1259/bjr.20210842
work_keys_str_mv AT sushentsevnikita serialchangesintumourmeasurementsandapparentdiffusioncoefficientsinprostatecancerpatientsonactivesurveillancewithandwithouthistopathologicalprogression
AT cagliciztok serialchangesintumourmeasurementsandapparentdiffusioncoefficientsinprostatecancerpatientsonactivesurveillancewithandwithouthistopathologicalprogression
AT rundoleonardo serialchangesintumourmeasurementsandapparentdiffusioncoefficientsinprostatecancerpatientsonactivesurveillancewithandwithouthistopathologicalprogression
AT kozlovvasily serialchangesintumourmeasurementsandapparentdiffusioncoefficientsinprostatecancerpatientsonactivesurveillancewithandwithouthistopathologicalprogression
AT salaevis serialchangesintumourmeasurementsandapparentdiffusioncoefficientsinprostatecancerpatientsonactivesurveillancewithandwithouthistopathologicalprogression
AT gnanapragasamvincentj serialchangesintumourmeasurementsandapparentdiffusioncoefficientsinprostatecancerpatientsonactivesurveillancewithandwithouthistopathologicalprogression
AT barretttristan serialchangesintumourmeasurementsandapparentdiffusioncoefficientsinprostatecancerpatientsonactivesurveillancewithandwithouthistopathologicalprogression